title: Autoimmune hepatitis triggered by adalimumab and allergic reactions after various anti-TNFα therapy agents in a patient with rheumatoid arthritis.
authors.forename: Jana
authors.initials: J
authors.lastname: Petríková
authors.forename: Peter
authors.initials: P
authors.lastname: Jarčuška
authors.forename: Marián
authors.initials: M
authors.lastname: Svajdler
authors.forename: Daniel
authors.initials: D
authors.lastname: Pella
authors.forename: Zelmíra
authors.initials: Z
authors.lastname: Macejová
mesh_terms: D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D003875:Drug Eruptions / Q000209:etiology; D016903:Drug Monitoring; D000068800:Etanercept; D005260:Female; D019693:Hepatitis, Autoimmune / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects*; D053590:Interleukin 1 Receptor Antagonist Protein / Q000008:administration & dosage*; D008099:Liver / Q000473:pathology; D008111:Liver Function Tests / Q000379:methods; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D053590:Interleukin 1 Receptor Antagonist Protein; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept